Treatment of bipolar disorder: A systematic review of available data and clinical perspectives

International Journal of Neuropsychopharmacology

Volumn 11, Issue 7, 2008, Pages 999-1029

  Fountoulakis, Konstantinos N ^a,c   Vieta, Eduard ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF BARCELONA   (Spain)

^c NONE   (Greece)

Author keywords

Anticonvulsants; Antidepressants; Antipsychotics; Bipolar disorder; Evidence based guidelines; Lithium; Mania; Mood stabilizers; Treatment

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE PLUS OLANZAPINE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TAMOXIFEN; TOPIRAMATE; TRANQUILIZER; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ALGORITHM; ARTICLE; ATAXIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BLOOD TOXICITY; BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DEPRESSION; DIABETES MELLITUS; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FAMILY THERAPY; GASTROINTESTINAL SYMPTOM; GROUP THERAPY; HAIR LOSS; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOMANIA; HYPOTHYROIDISM; INCREASED APPETITE; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; METABOLIC SYNDROME X; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; POLYDIPSIA; POLYURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RAPID CYCLING BIPOLAR DISORDER; RASH; SEDATION; SEIZURE; SIDE EFFECT; SKIN TOXICITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; GUIDELINES AS TOPIC; HUMANS; LONG-TERM CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 53049088876     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009231     Document Type: Article

References (336)

1. Anon (1997). Expert consensus guidelines are released for the treatment of bipolar disorder. Consensus Development Conferences. American Family Physician 55, 1447-1449.
2. AACAP (1997). AACAP official action. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 36, 138-157.
3. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP (2001). The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgraduate Medicine (Spec. No. 1-88), quiz 89-90.
4. Altshuler L, Kiriakos L, Calcagno J, Goodman R, Gitlin M, Frye M, Mintz J (2001). The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. Journal of Clinical Psychiatry 62, 612-616.
5. Altshuler L, Suppes T, Black D, Nolen WA, Keck Jr. PE, Frye MA, McElroy S, Kupka R, Grunze H, Walden J, et al. (2003). Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. American Journal of Psychiatry 160, 1252-1262.
6. Amsterdam JD, Garcia-Espana F (2000). Venlafaxine monotherapy in women with bipolar II and unipolar major depression. Journal of Affective Disorders 59, 225-229.
7. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Schweizer E, Beasley C (1998). Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. Journal of Clinical Psychopharmacology 18, 435-440.
8. Amsterdam JD, Shults J (2005a). Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression-lack of manic induction. Journal of Affective Disorders 87, 121-130.
9. Amsterdam JD, Shults J (2005b). Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology 20, 257-264.
10. Amsterdam JD, Shults J, Brunswick DJ, Hundert M (2004). Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar Disorders 6, 75-81.
11. APA (1994). Practice guideline for the treatment of patients with bipolar disorder. American Journal of Psychiatry 151 (Suppl.), 1-36.
12. APA (1995). American Psychiatric Association releases treatment guideline for bipolar disease. American Family Physician 51, 1605-1606.
13. APA (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 159 (Suppl.), 1-50.
14. Arnone D (2005). Review of the use of Topiramate for treatment of psychiatric disorders. Annals of General Psychiatry 4, 5.
15. Baastrup P (1964). The use of lithium in manic-depressive psychosis. Comprehensive Psychiatry 5, 396-408.
16. Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A (1970). Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 2, 326-330.
17. Baastrup PC, Schou M (1967). Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Archives of General Psychiatry 16, 162-172.
18. Baker RW, Goldberg JF, Tohen M, Milton DR, Stauffer VL, Schuh LM (2002). The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania. Bipolar Disorders 4, 43-49.
19. Baker RW, Tohen M, Fawcett J, Risser RC, Schuh LM, Brown E, Stauffer VL, Shao L, Tollefson GD (2003). Acute dysphoric mania: treatment response to olanzapine versus placebo. Journal of Clinical Psychopharmacology 23, 132-137.
20. Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck Jr. PE, McElroy SL, Sachs G, Vieta E, Welge JA, et al. (2003a). Olanzapine versus placebo in acute mania: treatment responses in subgroups. Journal of Clinical Psychopharmacology 23, 370-376.
21. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J (2006). Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disorders 8, 625-639.
22. Baldessarini RJ, Tondo L, Hennen J (2003b). Lithium treatment and suicide risk in major affective disorders: update and new findings. Journal of Clinical Psychiatry 64 (Suppl.), 44-52.
23. Ball JR, Mitchell PB, Corry JC, Skillecorn A, Smith M, Malhi GS (2006). A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. Journal of Clinical Psychiatry 67, 277-286.
24. Ballenger JC, Post RM (1980). Carbamazepine in manicdepressive illness: a new treatment. American Journal of Psychiatry 137, 782-790.
25. Barbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E (1997). Response to clozapine in acute mania is more rapid than that of chlorpromazine. International Clinical Psychopharmacology 12, 109-112.
26. Barreira P, Duckworth K, Goff D, Flannery Jr. RB (1999). Clinical practice guidelines: the Massachusetts experience in psychiatry. Harvard Review of Psychiatry 7, 230-232.
27. Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell BJ (1999). Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. Journal of Clinical Psychiatry 60, 9-21.
28. Bauer MS, Wisniewski SR, Marangell LB, Chessick CA, Allen MH, Dennehy EB, Miklowitz DJ, Thase ME, Sachs GS (2006). Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Journal of Clinical Psychiatry 67, 48-55.
29. Bech P (2001). Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. International Journal of Neuropsychopharmacology 4, 337-345.
30. Bech P (2002). The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure. CNS Drugs 16, 47-63.
31. Bech P (2006). The full story of lithium. A tribute to Mogens Schou (1918-2005). Psychotherapy and Psychosomatics 75, 265-269.
32. Bech P, Vendsborg PB, Rafaelsen OJ (1976). Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatrica Scandinavica 53, 70-81.
33. Berk M, Ichim L, Brook S (1999). Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. International Clinical Psychopharmacology 14, 339-343.
34. Bertilsson L, Tomson T (1986). Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine 10,11-epoxide: an update. Clinical Pharmacokinetics 11, 177-198.
35. Blackburn S, Oliart A, Garcia Rodriguez L, Perez Gutthann S (1998). Antiepileptics and blood dyscrasias: A cohort study. Pharmacotherapy 18, 1277.
36. Bottlender R, Rudolf D, Strauss A, Moller HJ (2001). Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. Journal of Affective Disorders 63, 79-83.
37. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, et al. (1994). Efficacy of divalproex vs lithiumand placebo in the treatment of mania. The Depakote Mania Study Group. Journal of the American Medical Association 271, 918-924.
38. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope Jr. HG, Chou JC, Keck Jr. PE, Rhodes LJ, et al. (2000a). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry 57, 481-489.
39. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HGJ, Chou J-Y, Keck PEJ, Rhodes LJ, et al. (2000b). A randomized placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Archives of General Psychiatry 57, 481-489.
40. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60, 392-400.
41. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K (2005). A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of Clinical Psychiatry 66, 111-121.
42. Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi-Saab W, Saltarelli M (2006). A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. Journal of Clinical Psychiatry 67, 1501-1510.
43. Bramness JG, Walby FA, Tverdal A (2007). The sales of antidepressants and suicide rates in Norway and its counties 1980-2004. Journal of Affective Disorders 102, 1-9.
44. Bridge J, Iyengar S, Salary C, Barbe R, Birmaher B, Pincus H, Ren L, Brent D (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. A meta-analysis of randomized controlled trials. Journal of the American Medical Association 297, 1683-1696.
45. Brown D, Silverstone T, Cookson J (1989). Carbamazepine compared to haloperidol in acute mania. International Clinical Psychopharmacology 4, 229-238.
46. Brown EB, McElroy SL, Keck Jr. PE, Deldar A, Adams DH, Tohen M, Williamson DJ (2006). A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. Journal of Clinical Psychiatry 67, 1025-1033.
47. Brugue E, Vieta E (2007). Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Progress in Neuropsychopharmacology and Biological Psychiatry 31, 275-282.
48. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G (2001). Lithium for maintenance treatment of mood disorders. Cochrane Database Systematic Reviews Issue 3, Art. no. CD003013.
49. Cade J (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 36, 349-352.
50. Cade J (1970). The story of lithium. In: Ayd F, Blackwell B (Eds.), Discoveries in Biological Psychiatry. Philadelphia: Lippincott.
51. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J (2003a). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 64, 1013-1024.
52. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry 60, 79-88.
53. Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M, White R, DeVeaugh-Geiss A, Thompson TR (2006). Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biological Psychiatry 59, 1061-1064.
54. Calabrese JR, Keck Jr. PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J (2005a). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162, 1351-1360.
55. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY (1996). Clozapine for treatment-refractory mania. American Journal of Psychiatry 153, 759-764.
56. Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Ganocy SJ, Findling RL (2005b). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. American Journal of Psychiatry 162, 2152-2161.
57. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. Journal of Clinical Psychiatry 61, 841-850.
58. Calabrese JR, Vieta E, Shelton MD (2003b). Latest maintenance data on lamotrigine in bipolar disorder. European Neuropsychopharmacology 13 (Suppl. 2), S57-66.
59. Carta MG, Zairo F, Mellino G, Hardoy MC, Vieta E (2006). An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients. Clinical Practice and Epideliology of Mental Health 2, 19.
60. Chengappa KN, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer DJ (2003). Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disorders 5, 1-5.
61. Chou JC, Czobor P, Charles O, Tuma I, Winsberg B, Allen MH, Trujillo M, Volavka J (1999). Acute mania: haloperidol dose and augmentation with lithium or lorazepam. Journal of Clinical Psychopharmacology 19, 500-505.
62. Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N (1993). A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Canadian Journal of Psychiatry 38 (Suppl. 4), S114-121.
63. Christodoulou GN, Lykouras EP (1982). Abrupt lithium discontinuation in manic-depressive patients. Acta Psychiatrica Scandinavica 65, 310-314.
64. Cipriani A, Pretty H, Hawton K, Geddes JR (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. American Journal of Psychiatry 162, 1805-1819.
65. Cipriani A, Rendell JM, Geddes JR (2006a). Haloperidol alone or in combination for acute mania. Cochrane Database Systematic Reviews. Issue 3, Article no. CD004362.
66. Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J (2006b). Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Systematic Reviews. Issue 4, Article no. CD003492.
67. Cohn JB, Collins G, Ashbrook E, Wernicke JF (1989). A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. International Clinical Psychopharmacology 4, 313-322.
68. Colom F, Vieta E, Daban C, Pacchiarotti I, Sanchez-Moreno J (2006). Clinical and therapeutic implications of predominant polarity in bipolar disorder. Journal of Affective Disorders 93, 13-17.
69. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, Corominas J (2003a). A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of General Psychiatry 60, 402-407.
70. Colom F, Vieta E, Reinares M, Martinez-Aran A, Torrent C, Goikolea JM, Gasto C (2003b). Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. Journal of Clinical Psychiatry 64, 1101-1105.
71. Colom F, Vieta E, Sanchez-Moreno J, Martinez-Aran A, Reinares M, Goikolea JM, Scott J (2005). Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disorders 7 (Suppl. 5), 32-36.
72. Colom F, Vieta E, Sanchez-Moreno J, Martinez-Aran A, Torrent C, Reinares M, Goikolea JM, Benabarre A, Comes M (2004). Psychoeducation in bipolar patients with comorbid personality disorders. Bipolar Disorders 6, 294-298.
73. Connemann BJ (2006). Lithium and suicidality revisited. American Journal of Psychiatry 163, 550 (author reply 550-551).
74. Cookson J, Keck Jr. PE, Ketter TA, Macfadden W (2007). Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. International Clinical Psychopharmacology 22, 93-100.
75. Cookson J, Silverstone T, Wells B (1981). Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. A test of the dopamine hypothesis. Acta Psychiatrica Scandinavica 64, 381-397.
76. Coxhead N, Silverstone T, Cookson J (1992). Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatrica Scandinavica 85, 114-118.
77. Cundall RL, Brooks PW, Murray LG (1972). A controlled evaluation of lithium prophylaxis in affective disorders. Psychological Medicine 2, 308-311.
78. Daly JJ, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Roose SP, Sackeim HA (2001). ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disorders 3, 95-104.
79. Davis JM, Janicak PG, Hogan DM (1999). Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatrica Scandinavica 100, 406-417.
80. Davis LL, Bartolucci A, Petty F (2005). Divalproex in the treatment of bipolar depression: a placebo-controlled study. Journal of Affective Disorders 85, 259-266.
81. DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, Nelson E, Strakowski SM (2006). A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry 45, 305-313.
82. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM (2002). A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry 41, 1216-1223.
83. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM (1997). Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. Journal of Clinical Psychiatry 58, 470-478.
84. Dennehy EB (2000). Guidelines for treatment of bipolar disorder. Current Psychiatry Reports 2, 316-321.
85. Dolberg OT, Dannon PN, Schreiber S, Grunhaus L (2002). Transcranial magnetic stimulation in patients with bipolar depression: a double blind, controlled study. Bipolar Disorders 4 (Suppl. 1), 94-95.
86. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M (2007). Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disorders 9, 618-627.
87. Dunn J, Ramey TS, Giller EL, English P, Riesenberg R, Trivedi J, Tochilov A (2006). Efiicacy and tolerability of ziprasidone in acute bipolar mania: twelve-week, double-blind study. 13th Association of European Psychiatrists, Munich, Germany.
88. Dunner DL, Stallone F, Fieve RR (1976). Lithium carbonate and affective disorders. V: a double-blind study of prophylaxis of depression in bipolar illness. Archives of General Psychiatry 33, 117-120.
89. Eden Evins A, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, Nierenberg AA, Sachs GS (2006). Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disorders 8, 168-174.
90. Einat H, Yuan P, Szabo ST, Dogra S, Manji HK (2007). Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 55, 123-131.
91. Emrich HM, von Zerssen D, Kissling W, Moller HJ (1981). Therapeutic effect of valproate in mania. American Journal of Psychiatry 138, 256.
92. Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A (1980). Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Archiv für Psychiatrie und Nervenkrankheiten 229, 1-16.
93. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W (2007). A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. International Clinical Psychopharmacology 22, 29-37.
94. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C (1991). Episode sequence in bipolar disorder and response to lithium treatment. American Journal of Psychiatry 148, 1237-1239.
95. FDA (2006). (http://www.fda.gov/cder/drug/antidepressants/default. htm). Accessed 16 October 2006.
96. Fieve RR, Kumbaraci T, Dunner DL (1976). Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. American Journal of Psychiatry 133, 925-929.
97. Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, Calabrese JR (2005). Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 44, 409-417.
98. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G (2008a). Treatment of bipolar depression: an update. Journal of Affective Disorders 109, 21-34.
99. Fountoulakis KN, Magiria S, Siamouli M, Panagiotidis P, Nimatoudis I, Iacovides A, Kaprinis GS (2007a). A seven-year follow-up of an extremely refractory bipolar I patient. CNS Spectrums 12, 733-734.
100. Fountoulakis KN, Siamouli M, Panagiotidis P, Magiria S, Kantartzis S, Iacovides A, Kaprinis GS (2008b). Ultra short manic-like episodes after antidepressant augmentation with modafinil. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 891-892.
101. Fountoulakis KN, Vieta E, Bouras C, Notaridis G, Giannakopoulos P, Kaprinis G, Akiskal H (2008c). A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? International Journal of Neuropsychopharmacology 11, 269-287.
102. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS (2005). Treatment guidelines for bipolar disorder: a critical review. Journal of Affective Disorders 86, 1-10.
103. Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, Fresno D, Giannakopoulos P, Kaprinis GS (2007b). Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Annals of General Psychiatry 6, 27.
104. Frances A, Docherty J, Kahn D (1996). The Expert Consensus Guideline Series: Treatment of Bipolar Disorder. Journal of Clinical Psychiatry 57 (Suppl. 12A), 1-88.
105. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC (1992). A double-blind comparison of valproate and lithium in the treatment of acute mania. American Journal of Psychiatry 149, 108-111.
106. Frye MA, Grunze H, Suppes T, McElroy SL, Keck Jr. PE, Walden J, Leverich GS, Altshuler LL, Nakelsky S, Hwang S, Mintz J, Post RM (2007). A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. American Journal of Psychiatry 164, 1242-1249.
107. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology 20, 607-614.
108. Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR (2006). Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. Journal of Clinical Psychiatry 67, 1721-1728.
109. Fyro B, Petterson U (1977). A double-blind study of the prophylactic effect of lithium in manic-depressive disease. Acta Psychiatrica Scandinavica 269, suppl: 17-22.
110. Gao K, Gajwani P, Elhaj O, Calabrese JR (2005). Typical and atypical antipsychotics in bipolar depression. Journal of Clinical Psychiatry 66, 1376-1385.
111. Garcia-Amador M, Pacchiarotti I, Valenti M, Sanchez RF, Goikolea JM, Vieta E (2006). Role of aripiprazole in treating mood disorders. Expert Reviews in Neurotherapeutics 6, 1777-1783.
112. Garfinkel PE, Stancer HC, Persad E (1980). A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. Journal of Affective Disorders 2, 279-288.
113. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM (2004). Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry 161, 217-222.
114. Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, Heath J (1998). Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry 37, 171-178.
115. Geller B, Cooper TB, Watts HE, Cosby CM, Fox LW (1992). Early findings from a pharmacokinetically designed double-blind and placebo-controlled study of lithium for adolescents comorbid with bipolar and substance dependency disorders. Progress in Neuropsychopharmacology and Biological Psychiatry 16, 281-299.
116. Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT (2007). Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. Journal of Clinical Psychiatry 68, 1840-1844.
117. Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, Sachs G (2006). Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatric Services 57, 660-665.
118. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ (2007). Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 164, 1356-1363.
119. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry 161, 1537-1547.
120. Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, Rush AJ (1998). Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. Journal of Clinical Psychiatry 59, 345-351.
121. Glen AI, Johnson AL, Shepherd M (1984). Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychological Medicine 14, 37-50.
122. Goldberg JF (2000). Treatment guidelines: current and future management of bipolar disorder. Journal of Clinical Psychiatry 61 (Suppl. 13), 12-18.
123. Goldberg JF, Allen MH, Miklowitz DA, Bowden CL, Endick CJ, Chessick CA, Wisniewski SR, Miyahara S, Sagduyu K, Thase ME, et al. (2005). Suicidal ideation and pharmacotherapy among STEP-BD patients. Psychiatric Services 56, 1534-1540.
124. Goldberg JF, Perlis RH, Ghaemi SN, Calabrese JR, Bowden CL, Wisniewski S, Miklowitz DJ, Sachs GS, Thase ME (2007). Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. American Journal of Psychiatry 164, 1348-1355.
125. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM (2003). Lamotrigine: a review of its use in bipolar disorder. Drugs 63, 2029-2050.
126. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM (2004). Spotlight on lamotrigine in bipolar disorder. CNS Drugs 18, 63-67.
127. Gonda X, Fountoulakis KN, Kaprinis G, Rihmer Z (2007). Prediction and prevention of suicide in patients with unipolar depression and anxiety. Annals of General Psychiatry 6, 23.
128. Gonzalez-Pinto A, Mosquera F, Alonso M, Lopez P, Ramirez F, Vieta E, Baldessarini RJ (2006). Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disorders 8, 618-624.
129. Goodwin FK, Murphy DL, Bunney Jr. WE (1969). Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study. Archives of General Psychiatry 21, 486-496.
130. Goodwin G, Bourgeois M, Conti L (1997). Treatment of bipolar depressive mood disorders: algorithms for pharmacotherapy. International Journal of Psychiatry in Clinical Practice 1, S9-S12.
131. Goodwin GM (1994). Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. British Journal of Psychiatry 164, 149-152.
132. Goodwin GM (2003). Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 17, 149-173; discussion 147.
133. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry 65, 432-441.
134. Gopal S, Steffens DC, Kramer ML, Olsen MK (2005). Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. Journal of Clinical Psychiatry 66, 1016-1020.
135. Greil W, Kleindienst N (1999a). The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. International Clinical Psychopharmacology 14, 277-281.
136. Greil W, Kleindienst N (1999b). Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. International Clinical Psychopharmacology 14, 283-285.
137. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B (1998). Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmacology 18, 455.
138. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Muller-Oerlinghausen B, Osterheider M, et al. (1997). Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. Journal of Affective Disorders 43, 151-161.
139. Grof P (2003). Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. Journal of Clinical Psychiatry 64 (Suppl. 5), 53-61.
140. Grof P, Alda M, Grof E, Zvolsky P, Walsh M (1994). Lithium response and genetics of affective disorders. Journal of Affective Disorders 32, 85-95.
141. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O'Donovan C, Alda M (2002). Is response to prophylactic lithium a familial trait? Journal of Clinical Psychiatry 63, 942-947.
142. Grunze H (2006). Treatment of acute bipolar depression: a European viewpoint. Journal of Bipolar Disorders: Reviews & Comentaries V, 3.
143. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Moller HJ (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World Journal of Biological Psychiatry 3, 115-124.
144. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Moller HJ (2003). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World Journal of Biological Psychiatry 4, 5-13.
145. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ (2004). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World Journal of Biological Psychiatry 5, 120-135.
146. Gunnell D, Ashby D (2004). Antidepressants and suicide: what is the balance of benefit and harm. British Medical Journal 329, 34-38.
147. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, Chou JC, Wassef A, Risch CS, Hirschfeld RM, et al. (2003). Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28, 1374-1382.
148. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P (2003). Association between antidepressant prescribing and suicide in Australia,
149. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA (2003). Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. Journal of Clinical Psychiatry 64, 144-151.
150. Himmelhoch J, Mulla D, Neil J, Detre T, Kupfer D (1976). Incidence and significance of mixed affective states in a bipolar population. Archives of General Psychiatry 3, 1062-1066.
151. Hirschfeld R (2005). Guideline Watch for the Practice Guideline for the Treatment of Patients With Bipolar Disorder. Arlington, VA: American Psychiatric Association.
152. Hirschfeld RM, Allen MH, McEvoy JP, Keck Jr. PE, Russell JM (1999). Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. Journal of Clinical Psychiatry 60, 815-818.
153. Hirschfeld RM, Keck Jr. PE, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F (2004). Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. American Journal of Psychiatry 161, 1057-1065.
154. Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ (2006). Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. Journal of Clinical Psychiatry 67, 1246-1252.
155. Houston JP, Lipkovich IA, Ahl J, Rotelli MD, Baker RW, Bowden CL (2005). Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium. Journal of Psychiatric Research 41, 616-621.
156. Hullin RP, McDonald R, Allsopp MN (1972). Prophylactic lithium in recurrent affective disorders. Lancet 1, 1044-1046.
157. Ichim L, Berk M, Brook S (2000). Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Annals of Clinical Psychiatry 12, 5-10.
158. Jobson K (1997). International Psychopharmacology Algorithm Project: algorithms in psychopharmacology. International Journal of Psychiatry in Clinical Practice 1, S3-S8.
159. Kafantaris V, Coletti DJ, Dicker R, Padula G, Pleak RR, Alvir JM (2004). Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry 43, 984-993.
160. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A (1982). Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Archives of General Psychiatry 39, 1065-1069.
161. Keck P, Sanchez R, Torbeyns A, Marcus R, McQuade R, Forbes A (2007a). Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized placebo-and lithium- controlled study (Study CN138-135). American Psychiatric Association 160th Annual Meeting, San Diego CA, USA.
162. Keck Jr. PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R (2007b). Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. Journal of Clinical Psychiatry 68, 1480-1491.
163. Keck Jr. PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R (2006). A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Journal of Clinical Psychiatry 67, 626-637.
164. Keck Jr. PE, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M (2005). Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. Journal of Clinical Psychiatry 66, 611-616.
165. Keck Jr. PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G (2003a). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 160, 1651-1658.
166. Keck Jr. PE, Versiani M, Potkin S, West SA, Giller E, Ice K (2003b). Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. American Journal of Psychiatry 160, 741-748.
167. Kessing LV, Sondergard L, Kvist K, Andersen PK (2005). Suicide risk in patients treated with lithium. Archives of General Psychiatry 62, 860-866.
168. Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, Tohen M (2006). Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. Journal of Clinical Psychiatry 67, 95-101.
169. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M (2005). Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. British Journal of Psychiatry 187, 229-234.
170. Klein DF (1967). Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry 16, 118-126.
171. Klein E, Bental E, Lerer B, Belmaker RH (1984). Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Archives of General Psychiatry 41, 165-170.
172. Klein HE, Broucek B, Greil W (1981). Lithium withdrawal triggers psychotic states. British Journal of Psychiatry 139, 255-256.
173. Kleindienst N, Greil W (2000). Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 42 (Suppl. 1), 2-10.
174. Kleindienst N, Greil W (2002). Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder. Psychological Medicine 32, 493-501.
175. Kujawa M, Turner N, Turkoz L, MacFadden W, Bossie C, Alphs L (2008). Frequently relapsing bipolar disorder: evidence for an effective treatment. Schizophrenia Researchearch 98, 5.
176. Kulkarni J, Garland KA, Scaffidi A, Headey B, Anderson R, de Castella A, Fitzgerald P, Davis SR (2006). A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 31, 543-547.
177. Kushner SF, Khan A, Lane R, Olson WH (2006). Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disorders 8, 15-27.
178. Kusumakar V, Yatham L, Parikh S (1997). Bipolar disorder: a summary of clinical issues and treatment options. Halifax, Nova Scotia: CANMAT Monograph.
179. Lange F (1894). The Most Important Pychiatric Disorders. Copenhagen: Gyldendal.
180. Lecrubier Y, Bech P (2007). The Ham D(6) is more homogenous and as sensitive as the Ham D(17). European Psychiatry 22, 252-255.
181. Lehman AF, Steinwachs DM (1998). Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin 24, 1-10.
182. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM (1992). Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. Journal of Clinical Psychiatry 53, 47-52.
183. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S (1987). Carbamazepine versus lithium in mania: a double-blind study. Journal of Clinical Psychiatry 48, 89-93.
184. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck Jr. PE, Kupka RW, Denicoff KD, Nolen WA, Grunze H, et al. (2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry 163, 232-239.
185. Licht RW, Vestergaard P, Kessing LV, Larsen JK, Thomsen PH (2003). Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatrica Scandinavica 108 (Suppl. 419), 1-22.
186. Lusznat RM, Murphy DP, Nunn CM (1988). Carbamazepine vs lithium in the treatment and prophylaxis of mania. British Journal of Psychiatry 153, 198-204.
187. Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G (2003). Valproate for acute mood episodes in bipolar disorder. Cochrane Database Systematic Reviews. Issue 1, Article no. CD004052.
188. Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM (2001). Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Systematic Reviews. Issue 3, Article no. CD003196.
189. Mander AJ, Loudon JB (1988). Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 2, 15-17.
190. Manji HK, Chen G (2002). PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Molecular Psychiatry 7 (Suppl. 1), S46-56.
191. Margo A, McMahon P (1982). Lithium withdrawal triggers psychosis. British Journal of Psychiatry 141, 407-410.
192. McClellan J, Werry J (1997). Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. American Academy of Child and Adolescent Psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry 36 (Suppl.) 157S-176S.
193. McElroy S, Young A, Carlsson A, Olausson B, Nordenhem A, Paulsson B, Brecher M (2008). Double-blind, randomized, placebo-controlled study of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). Conference of the International Society for Bipolar Disorders, Delhi and Agra, India.
194. McElroy SL, Dessain EC, Pope Jr. HG, Cole JO, Keck Jr. PE, Frankenberg FR, Aizley HG, O'Brien S (1991). Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. Journal of Clinical Psychiatry 52, 411-414.
195. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM (1996). A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. Journal of Clinical Psychiatry 57, 142-146.
196. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J (2005). Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. European Neuropsychopharmacology 15, 573-585.
197. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A (2001). A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology 21, 389-397.
198. Melia PI (1970). Prophylactic lithium: a double-blind trial in recurrent affective disorders. British Journal of Psychiatry 116, 621-624.
199. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Kogan JN, Sachs GS, Thase ME, Calabrese JR, Marangell LB, Ostacher MJ, et al. (2007a). Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. American Journal of Psychiatry 164, 1340-1347.
200. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN, Nierenberg AA, Calabrese JR, Marangell LB, Gyulai L, et al. (2007b). Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Archives of General Psychiatry 64, 419-426.
201. Moller H, Bottlender R, Grunze H, Streuss A, Wittmann J (2001). Are antidepressant less effective in the acute treatment of bipolar I compared to unipolar depression? Journal of Affective Disorders 67, 141-146.
202. Montgomery DB (2001). ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. European College of Neuropsychopharmacology. European Neuropsychopharmacology 11, 79-88.
203. Mudur G (2006). Indian study sparks debate on the use of placebo in psychiatry trials. British Medical Journal 332, 566.
204. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J (2000). Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. Journal of Clinical Psychopharmacology 20, 195-203.
205. Nahas Z, Kozel FA, Li X, Anderson B, George MS (2003). Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disorders 5, 40-47.
206. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry 158, 906-912.
207. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS (2006). Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry 163, 210-216.
208. Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, Ming L, Gaohua W, Xinbao Z, Huichun L, Liang S (2008). Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. Journal of Affective Disorders 105, 101-108.
209. O'Dowd A (2006). NICE issues new guidance to improve the treatment of bipolar disorder. British Medical Journal 333, 220.
210. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M (1979). Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berlin), 66, 211-217.
211. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S (1981). A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berlin), 73, 95-96.
212. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K (1990). Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 23, 143-150.
213. Oulis P, Karapoulios E, Kouzoupis AV, Masdrakis VG, Kontoangelos KA, Makrilakis K, Karakatsanis NA, Papageorgiou C, Katsilambros N, Soldatos CR (2007). Oxcarbazepine as monotherapy of acute mania in insufficiently controlled type-1 diabetes mellitus: a case-report. Annals of General Psychiatry 6, 25.
214. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G (2000). Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disorders 2, 249-255.
215. Parker G, Tully L, Olley A, Hadzi-Pavlovic D (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders 92, 205-214.
216. Patel V (2006). Ethics of placebo-controlled trial in severe mania. Indian Journal of Medical Ethics 3, 11-12.
217. Perlis RH, Baker RW, Zarate Jr. CA, Brown EB, Schuh LM, Tohen M (2006a). Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. Journal of Clinical Psychiatry 67, 1747-1753.
218. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck Jr. PE (2006b). Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 67, 509-516.
219. Persson G (1972). Lithium prophylaxis in affective disorders. Acta Psychiatrica Scandinavica 48, 462-479.
220. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS (1986). The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. Journal of Clinical Psychiatry 47, 490-494.
221. Platman SR (1970). A comparison of lithium carbonate and chlorpromazine in mania. American Journal of Psychiatry 127, 351-353.
222. Pokorny AD, Prien RF (1974). Lithium in treatment and prevention of affective disorder. A VA-NIMH collaborative study. Disorders of the Nervous System 35, 327-333.
223. Pope Jr. HG, McElroy SL, Keck Jr. PE, Hudson JI (1991). Valproate in the treatment of acute mania. A placebo-controlled study. Archives of General Psychiatry 48, 62-68.
224. Post R, Leverich G, Altshuler L, Mikalauskas K (1992). Lithium-discontinuation-induced refractoriness: Preliminary observations. American Journal of Psychiatry 149, 1727.
225. Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck Jr. PE, McElroy SL, Denicoff KD, Leverich GS, Kupka R, Nolen WA (2001). Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders 3, 259-265.
226. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE, Denicoff KD, et al. (2006). Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry 189, 124-131.
227. Potkin SG, Keck Jr. PE, Segal S, Ice K, English P (2005). Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. Journal of Clinical Psychopharmacology 25, 301-310.
228. Prien RF (1984). NIMH report. Five-center study clarifies use of lithium, imipramine for recurrent affective disorders. Hospital and Community Psychiatry 35, 1097-1098.
229. Prien RF, Caffey Jr. EM (1977). Long-term maintenance drug therapy in recurrent affective illness: current status and issues. Disorders of the Nervous System 38, 981-992.
230. Prien RF, Caffey Jr. EM, Klett CJ (1972). Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Archives of General Psychiatry 26, 146-153.
231. Prien RF, Caffey Jr. EM, Klett CJ (1973a). Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Archives of General Psychiatry 28, 337-341.
232. Prien RF, Klett CJ, Caffey Jr. EM (1973b). Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Archives of General Psychiatry 29, 420-425.
233. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE (1984). Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Archives of General Psychiatry 41, 1096-1104.
234. Privitera MR, Maharaj K (2003). Mania from dose-related ziprasidone augmentation of an SSRI. Journal of Clinical Psychiatry 64, 1393-1394.
235. Quitkin FM, Kane J, Rifkin A, Ramos-Lorenzi JR, Nayak DV (1981a). Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Archives of General Psychiatry 38, 902-907.
236. Quitkin FM, Kane JM, Rifkin A, Ramos-Lorenzi JR, Saraf K, Howard A, Klein DF (1981b). Lithium and imipramine in the prophylaxis of unipolar and bipolar II depression: a prospective, placebo-controlled comparison [Proceedings]. Psychopharmacological Bulletin 17, 142-144.
237. Ramasubbu R (2001). Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Acta Psychiatrica Scandinavica 104, 236-238; discusion 238-239.
238. Reinares M, Vieta E, Colom F, Martinez-Aran A, Torrent C, Comes M, Goikolea JM, Benabarre A, Sanchez-Moreno J (2004). Impact of a psychoeducational family intervention on caregivers of stabilized bipolar patients. Psychotherapy and Psychosomatics 73, 312-319.
239. Rendell JM, Gijsman HJ, Bauer MS, Goodwin GM, Geddes GR (2006). Risperidone alone or in combination for acute mania. Cochrane Database of Systematic Reviews. Issue 1, Article no. CD004043.
240. Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR (2003). Olanzapine alone or in combination for acute mania. Cochrane Database of Systematic Reviews. Issue 3, Article no. CD004040.
241. Rihmer Z (2004). Decreasing national suicide rates - fact or fiction? World Journal of Biological Psychiatry 5, 55-56.
242. Rihmer Z, Akiskal H (2006). Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. Journal of Affective Disorders 94, 3-13.
243. Rihmer Z, Belso N, Kalmar S (2001). Antidepressants and suicide prevention in Hungary. Acta Psychiatrica Scandinavica 103, 238-239.
244. Rosa AR, Andreazza AC, Kunz M, Gomes F, Santin A, Sanchez-Moreno J, Reinares M, Colom F, Vieta E, Kapczinski F (2008). Predominant polarity in bipolar disorder: Diagnostic implications. Journal of Affective Disorders 107, 45-51.
245. Rouillon F, Serrurier D, Miller H, Gerard M (1991). Prophylactic efficacy of maprotiline on unipolar depression relapse. Journal of Clinical Psychiatry 52, 423-431.
246. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR (2006). Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 67, 1698-1706.
247. Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM, Shores-Wilson K, et al. (2003). Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Journal of Clinical Psychiatry 64, 357-369.
248. Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi MH, Swann AC, Biggs MM, et al. (1999). Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. Journal of Clinical Psychiatry 60, 284-291.
249. Saba G, Rocamora JF, Kalalou K, Benadhira R, Plaze M, Lipski H, Januel D (2004). Repetitive transcranial magnetic stimulation as an add-on therapy in the treatment of mania: a case series of eight patients. Psychiatry Research 128, 199-202.
250. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE (2004). Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disorders 6, 213-223.
251. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T (2006). Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Journal of Psychopharmacology 20, 536-546.
252. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov 3rd A, Pultz JA, Sanchez R, Marcus RN, Crandall DT (2007a). Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. Journal of Clinical Psychiatry 68, 1377-1383.
253. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. American Journal of Psychiatry 159, 1146-1154.
254. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, et al. (2007b). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine 356, 1711-1722.
255. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP (2000). The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgraduate Medicine (Spec. No.), 1-104.
256. Schaffer A, Zuker P, Levitt A (2006). Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. Journal of Affective Disorders 96, 95-99.
257. Schneck CD, Miklowitz DJ, Miyahara S, Araga M, Wisniewski S, Gyulai L, Allen MH, Thase ME, Sachs GS (2008). The Prospective Course of Rapid-Cycling Bipolar Disorder: Findings From the STEP-BD. American Journal of Psychiatry, 165, 370-377.
258. Schou M (1997). Forty years of lithium treatment. Archives of General Psychiatry 54, 9.
259. Schou M, Baastrup PC (1967). Lithium treatment of manic-depressive disorder. Dosage and control. Journal of the American Medical Association 201, 696-698.
260. Schou M, Juel-Nielsen N, Stromgren E, Voldby H (1954). The treatment of manic psychosis by the administration of lithium salts. Journal of Neurology Neurosurgery and Psychiatry 17, 250-260.
261. Scott J, Colom F, Vieta E (2007). A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. International Journal of Neuropsychopharmacology 10, 123-129.
262. Segal J, Berk M, Brook S (1998). Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clinical Neuropharmacology 21, 176-180.
263. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, Tohen M (2004). Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clinical Therapeutics 26, 125-134.
264. Shopsin B, Gershon S, Thompson H, Collins P (1975). Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Archives of General Psychiatry 32, 34-42.
265. Sikdar S, Kulhara P, Avasthi A, Singh H (1994). Combined chlorpromazine and electroconvulsive therapy in mania. British Journal of Psychiatry 164, 806-810.
266. Silverstone PH, Bell EC, Willson MC, Dave S, Wilman AH (2005). Lithium alters brain activation in bipolar disorder in a task- and state-dependent manner: an fMRI study. Annals of General Psychiatry 4, 14.
267. Simhandl C, Denk E, Thau K (1993). The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. Journal of Affective Disorders 28, 221-231.
268. Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V, Sharpley PH, Small IF (1988). Electroconvulsive treatment compared with lithium in the management of manic states. Archives of General Psychiatry 45, 727-732.
269. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ (1995). Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacological Bulletin 31, 265-272.
270. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, Small IF (1991). Carbamazepine compared with lithium in the treatment of mania. Archives of General Psychiatry 48, 915-921.
271. Small JG, Small IF, Moore DF (1971). Experimental withdrawal of lithium in recovered manic-depressive patients: a report of five cases. American Journal of Psychiatry 127, 1555-1558.
272. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D (2007). Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatrica Scandinavica 115, 12-20.
273. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F (2005). Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. European Neuropsychopharmacology 15, 75-84.
274. Stoll K, Goncalves N, Krober H, Demisch K, Bellaire W (1989). Use of Carbamazepine in affective illness. In: Lerer G, Gershon S (Eds.), New Directions in Affective Disorders (pp. 540-544). New York: Springer-Verlag.
275. Suppes T, Brown E, Schuh LM, Baker RW, Tohen M (2005). Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. Journal of Affective Disorders 89, 69-77.
276. Suppes T, Calabrese J, Mitchell P, Pazzaglia P, Potter W, Zarin D (1995). Algorithms for the treatment of bipolar manic-depressive illness. Psychopharmacological Bulletin 31, 469-474.
277. Suppes T, Dennehy EB, Swann AC, Bowden CL, Calabrese JR, Hirschfeld RM, Keck Jr. PE, Sachs GS, Crismon ML, Toprac MG, Shon SP (2002). Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. Journal of Clinical Psychiatry 63, 288-299.
278. Suppes T, Eudicone J, McQuade R, Pikalov 3rd A, Carlson B (2008a). Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. Journal of Affective Disorders 107, 145-154.
279. Suppes T, Liu S, Brecher M, Paulsson B, Lazarus A (2008b). Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: a placebo-controlled, randomized multicenter trial (trial D1447C00127). Bipolar Disorders 10 (Suppl. 1).
280. Suppes T, Rush AJ, Dennehy EB, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Brown ES, Biggs MM, Shores-Wilson K, et al. (2003). Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. Journal of Clinical Psychiatry 64, 370-382.
281. Suppes T, Swann AC, Dennehy EB, Habermacher ED, Mason M, Crismon ML, Toprac MG, Rush AJ, Shon SP, Altshuler KZ (2001). Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. Journal of Clinical Psychiatry 62, 439-447.
282. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999). Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. American Journal of Psychiatry 156, 1164-1169.
283. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R (2008). Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology 28, 13-20.
284. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology 26, 600-609.
285. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA (2002a). Olanzapine versus divalproex in the treatment of acute mania. American Journal of Psychiatry 159, 1011-1017.
286. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL (2006). Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. American Journal of Psychiatry 163, 247-256.
287. Tohen M, Castillo J, Baldessarini RJ, Zarate Jr. C, Kando JC (1995). Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. American Journal of Psychiatry 152, 413-418.
288. Tohen M, Castillo J, Cole JO, Miller MG, de los Heros R, Farrer RJ (1991). Thrombocytopenia associated with carbamazepine: a case series. Journal of Clinical Psychiatry 52, 496-498.
289. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, et al. (2004). Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. British Journal of Psychiatry 184, 337-345.
290. Tohen M, Chengappa KN, Suppes T, Zarate Jr. CA, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, et al. (2002b). Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Archives of General Psychiatry 59, 62-69.
291. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW, et al. (2003a). A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Archives of General Psychiatry 60, 1218-1226.
292. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, et al. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry 162, 1281-1290.
293. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, et al. (2000). Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Archives of General Psychiatry 57, 841-849.
294. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka
295. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, et al. (2007). Olanzapine versus placebo in the treatment of adolescents with bipolar mania. American Journal of Psychiatry 164, 1547-1556.
296. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, et al. (1999). Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. American Journal of Psychiatry 156, 702-709.
297. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, et al. (2003c). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 60, 1079-1088.
298. Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, Thase ME, Sachs GS (2007). Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Journal of Clinical Psychiatry 68, 1472-1479.
299. Van der Loos M, Mulder P, Hartong E (in press). Efficacy and safety of lamotrigine as add-on to lithium in the treatment of bipolar depression: a multi-center, doubleblind, placebo-controlled trial. Journal of Clinical Psychiatry.
300. Vasudev K, Goswami U, Kohli K (2000). Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berlin) 150, 15-23.
301. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Swanink R, Iwamoto T (2005a). Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. British Journal of Psychiatry 187, 235-242.
302. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W (2007a). Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebocontrolled study. Bipolar Disorders 9, 413-425.
303. Vieta E, Carne X (2005). The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychotherapy and Psychosomatics 74, 10-16.
304. Vieta E, Cruz N, Garcia-Campayo J, De Arce R, Crespo J, Valles V, Perez-Blanco J, Roca E, Olivares J, Morinigo A, et al. (2008). A double-blind, randomized, placebo controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. International Journal of Neuropsychopharmacology 17, 1-8.
305. Vieta E, Eggens I, Persson I, Paulsson B, Brecher M (2007b). Efficacy and safety of quetiapine in combination with lithium or divalproex as maintenance treatment for patients with bipolar I disorder: results from an international, multicenter, randomized, double-blind, parallel-group trial (Trial 126). Presented at the 20th ECNP Congress Vienna.
306. Vieta E, Goikolea JM (2005). Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disorders 7 (Suppl. 4), 21-33.
307. Vieta E, Manuel Goikolea J, Martinez-Aran A, Comes M, Verger K, Masramon X, Sanchez-Moreno J, Colom F (2006a). A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Journal of Clinical Psychiatry 67, 473-477.
308. Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M (2002). A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of Clinical Psychiatry 63, 508-512.
309. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M (2005b). Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Current Medical Research Opinion 21, 923-934.
310. Vieta E, Nolen WA, Grunze H, Licht RW, Goodwin G (2005c). A European perspective on the Canadian guidelines for bipolar disorder. Bipolar Disorders 7 (Suppl. 3), 73-76.
311. Vieta E, Ramey T, Keller D, English P, Loebel A, Miceli J (in press a). Ziprasidone in the treatment of acute mania: A 12-week placebo-controlled, haloperidol-referenced study. Journal of Psychopharmacology.
312. Vieta E, Ros S, Goikolea JM, Benabarre A, Popova E, Comes M, Capapey J, Sanchez-Moreno J (2005d). An open-label study of amisulpride in the treatment of mania. Journal of Clinical Psychiatry 66, 575-578.
313. Vieta E, T'joen C, McQuade RD, Carson WH, Marcus RN, Sanchez R, Owen R, Nameche L (in press b). Efficacy of adjuntive aripiprazol to valproate or lithium in bipolar patients with mania who were partially non-responsive to valproate/lithium: a placebo-controlled study. American Journal of Psychiatry.
314. Vieta E, Thomas P, the SOLMANIA Study Group (2006b). An open-label, randomised, comparative trial of the effectiveness and safety of combination treatment with valproate and amisulpride in the treatment of acute mania in bipolar disorder. Presented at the Vth European Stanley Meeting on Bipolar Disorder, Barcelona, Spain.
315. Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA (2002). Gabapentin augmentation therapy in bipolar depression. Bipolar Disorders 4, 296-301.
316. Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM (1987). The effect of carbamazepine and lithium on remission from affective illness. British Journal of Psychiatry 150, 180-182.
317. Weisler R, Dunn J, English P (2003). Adjunctive ziprasidone for acute bipolar mania: randomized, placebo-controlled trial. 4th International Forum on Mood and Anxiety Disorders, Monte Carlo, Monaco.
318. Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Ketter TA, Keck PE, Swann A, Kalali A (2006). Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 20, 219-231.
319. Weisler RH, Kalali AH, Ketter TA (2004). A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. Journal of Clinical Psychiatry 65, 478-484.
320. Weisler RH, Keck Jr. PE, Swann AC, Cutler AJ, Ketter TA, Kalali AH (2005). Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 66, 323-330.
321. Wilson KC, Scott M, Abou-Saleh M, Burns R, Copeland JR (1995). Long-term effects of cognitive-behavioural therapy and lithium therapy on depression in the elderly. British Journal of Psychiatry 167, 653-658.
322. Wittington C, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363, 1341-1345.
323. Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC, Silverstone PH (2004). Brain choline concentrations may not be altered in euthymic bipolar disorder patients chronically treated with either lithium or sodium valproate. Annals of General Hospital Psychiatry 3, 13.
324. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A (2003). Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. British Journal of Psychiatry 182, 141-147.
325. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, et al. (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders 7 (Suppl. 3), 5-69.
326. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S (2006). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disorders 8, 721-739.
327. Yatham LN, Paulsson B, Mullen J, Vagero AM (2004). Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. Journal of Clinical Psychopharmacology 24, 599-606.
328. Yatham LN, Vieta E, Young AH, Moller HJ, Paulsson B, Vagero M (2007). A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. International Clinical Psychopharmacology 22, 212-220.
329. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF (2008). Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Archives of General Psychiatry 65, 255-263.
330. Young A, McElroy S, Chang W, Olausson B, Paulsson B, Brecher M (2008). A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I). Conference of the International Society for Bipolar Disorders. Delhi and Agra, India.
331. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I (2000). Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. American Journal of Psychiatry 157, 124-126.
332. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW (2002). A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. Journal of Clinical Psychiatry 63, 1148-1155.
333. Zarate Jr. CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK (2004). Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry 56, 54-60.
334. Zarate Jr. CA, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK (2007). Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 9, 561-570.
335. Zarate Jr. CA, Tohen M (2004). Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. American Journal of Psychiatry 161, 169-171.
336. Zhu B, Tunis SL, Zhao Z, Baker RW, Lage MJ, Shi L, Tohen M (2005). Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Current Medical Research Opinion 21, 555-564.